# Lymphoma Diagnosis and Treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the classification, molecular profiling, genetic pathogenesis, and treatment strategies for various types of lymphoid neoplasms, including Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma. It also explores the use of PET imaging, rituximab therapy, and gene expression profiling to predict survival and guide treatment decisions. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10185 |
| Works | 375 |

## Topic papers all

Showing 15 of 375.

- [Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics](https://scholariq.org/papers/investigation-of-the-freely-available-easy-to-use-software-ezr-for-medical/)
- [Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling](https://scholariq.org/papers/distinct-types-of-diffuse-large-b-cell-lymphoma-identified-by-gene-expression/)
- [Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.](https://scholariq.org/papers/rituximab-chimeric-anti-cd20-monoclonal-antibody-therapy-for-relapsed-indolent/)
- [Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease \[see comments\]](https://scholariq.org/papers/kaposi-s-sarcoma-associated-herpesvirus-like-dna-sequences-in-multicentric/)
- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group](https://scholariq.org/papers/role-of-imaging-in-the-staging-and-response-assessment-of-lymphoma-consensus-of/)
- [Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor](https://scholariq.org/papers/chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell/)
- [Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/revisions-to-the-staging-and-classification-of-mycosis-fungoides-and-sezary/)
- [Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/rituximab-chop-versus-chop-alone-or-with-maintenance-rituximab-in-older-patients/)
- [Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma](https://scholariq.org/papers/use-of-positron-emission-tomography-for-response-assessment-of-lymphoma/)
- [Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci](https://scholariq.org/papers/genome-wide-association-study-meta-analysis-identifies-seven-new-rheumatoid/)
- [Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma](https://scholariq.org/papers/tumor-associated-macrophages-and-survival-in-classic-hodgkin-s-lymphoma/)
- [EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors](https://scholariq.org/papers/eml4-alk-mutations-in-lung-cancer-that-confer-resistance-to-alk-inhibitors/)
- [Non-Hodgkin's Lymphoma in 90 Homosexual Men](https://scholariq.org/papers/non-hodgkin-s-lymphoma-in-90-homosexual-men/)
- [An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era](https://scholariq.org/papers/an-enhanced-international-prognostic-index-nccn-ipi-for-patients-with-diffuse/)

## Topic primary papers

Showing 15 of 136.

- [Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling](https://scholariq.org/papers/distinct-types-of-diffuse-large-b-cell-lymphoma-identified-by-gene-expression/)
- [Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.](https://scholariq.org/papers/rituximab-chimeric-anti-cd20-monoclonal-antibody-therapy-for-relapsed-indolent/)
- [Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group](https://scholariq.org/papers/role-of-imaging-in-the-staging-and-response-assessment-of-lymphoma-consensus-of/)
- [Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/rituximab-chop-versus-chop-alone-or-with-maintenance-rituximab-in-older-patients/)
- [Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma](https://scholariq.org/papers/use-of-positron-emission-tomography-for-response-assessment-of-lymphoma/)
- [Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma](https://scholariq.org/papers/tumor-associated-macrophages-and-survival-in-classic-hodgkin-s-lymphoma/)
- [An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era](https://scholariq.org/papers/an-enhanced-international-prognostic-index-nccn-ipi-for-patients-with-diffuse/)
- [Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study](https://scholariq.org/papers/early-relapse-of-follicular-lymphoma-after-rituximab-plus-cyclophosphamide/)
- [Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma](https://scholariq.org/papers/adapted-treatment-guided-by-interim-pet-ct-scan-in-advanced-hodgkin-s-lymphoma/)
- [Obinutuzumab for the First-Line Treatment of Follicular Lymphoma](https://scholariq.org/papers/obinutuzumab-for-the-first-line-treatment-of-follicular-lymphoma/)
- [Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/polatuzumab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/)
- [Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project](https://scholariq.org/papers/follicular-lymphoma-international-prognostic-index-2-a-new-prognostic-index-for/)
- [Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial](https://scholariq.org/papers/brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell/)
- [MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program](https://scholariq.org/papers/myc-bcl2-protein-coexpression-contributes-to-the-inferior-survival-of-activated/)
- [Somatic RHOA mutation in angioimmunoblastic T cell lymphoma](https://scholariq.org/papers/somatic-rhoa-mutation-in-angioimmunoblastic-t-cell-lymphoma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.